Clinical Trials & Research
Leading Research. Promising Drug Trials.
Over the past 40 years, Florida Cancer Affiliates – Ocala Oncology patients have provided our patients access to cutting-edge and innovative clinical trials in a comfortable and convenient setting. One of the largest and most reputable community-based research networks in the world, US Oncology Research has contributed to over 70 FDA-approved cancer therapies and approximately one-third of all FDA-approved oncology therapies. It also specializes in Phase I–IV oncology clinical trials and has participated in over 1,600 investigator-initiated and sponsor-initiated trials since its inception. The program brings innovative therapies and clinical trials to practices and patients in communities across the nation to help advance the science of cancer care while offering the best possible treatments and improved patient outcomes.
We are proud of our new role in the research and development of vital new cancer therapies through independent studies. This will alow us broader range of opportunities to offer our patients . We are dedicated to advancing cancer care by leading and participating in clinical trials that test the safety and efficiency of new or modified treatments. And we are deeply committed to bringing clinical trials to our community, offering patients an opportunity to help shape the future of cancer treatment, while benefitting from the very latest in clinical trials. Florida Cancer Affiliates- Ocala Oncology is constantly offering eligible patients opportunities to join new trials.
At Florida Cancer Affiliates – Ocala Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options.We are pleased to share this list of clinical trials currently enrolling at our practice.
TOP ENROLLING CLINICAL TRIAL SITE IN THE UNITED STATES
Congratulation to Dr. Ketan Doshi and the research team at Ocala Oncology/Florida Cancer Affiliates for being recognized as the top enrolling site in the United States for a Follicular Lymphoma study evaluating patients receiving the combination of Ibrutinib and Rituximab for the treatment of follicular lymphoma. View Clinical Trials
